Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

European Sapheon™ Closure System Observational ProspectivE (eSCOPE) Study (eSCOPE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01570101
Recruitment Status : Completed
First Posted : April 4, 2012
Last Update Posted : May 3, 2016
Information provided by (Responsible Party):
Medtronic Endovascular

Brief Summary:
The primary objective for this clinical study is to assess the role of the CE Marked Sapheon Closure System in closure of incompetent great saphenous veins "GSV" in a routine clinical setting.

Condition or disease Intervention/treatment Phase
Venous Insufficiency of Leg Device: CE Marked Sapheon Closure System Not Applicable

Detailed Description:
This is a post market, observational study of closure of the great saphenous vein "GSV". Efficacy and safety (adverse events) will be compared to appropriate literature reports to determine if the results of the treatment of reflux disease with the Sapheon Closure System are consistent with or better than the expectations of the medical community for alternative treatments, specifically Laser Thermal Ablation and Radiofrequency Ablation. Additional comparison points may include measurements of pain and/or length of time to return to work.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Post Market Study - "European Observational Study of the Sapheon™ Closure System for the Definitive Treatment of Incompetent Great Saphenous Veins: A Prospective Single Arm Multicenter Clinical Observational Study"
Study Start Date : December 2011
Actual Primary Completion Date : July 2013
Actual Study Completion Date : September 2015

Arm Intervention/treatment
Experimental: CE Marked Sapheon Closure System in GSV
CE Marked Sapheon Closure System in closure of incompetent great saphenous veins "GSV" in a routine clinical setting.
Device: CE Marked Sapheon Closure System
CE Marked Sapheon Closure System in closure of incompetent great saphenous veins "GSV" in a routine clinical setting.

Primary Outcome Measures :
  1. Comparative Duplex Ultrasound [ Time Frame: Immediately Post-procedure ]
    The Primary endpoint is a change in duplex ultrasound immediately post-procedure as compared to the pre-procedure duplex ultrasound, proving great saphenous vein closure with lack of pathological reflux.

Secondary Outcome Measures :
  1. Safety [ Time Frame: Immediately post-op through 6 month Follow-up "FU" ]
    The Secondary endpoint is safety, reflected by the rate of occurrence of all adverse events (procedure and non-procedure related; serious and non-serious).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥18 years and ≤ 70 years of age.
  • Symptomatic primary Great Saphenous Vein "GSV" incompetence diagnosed by clinical symptoms, with or without visible varicosities, and confirmed by duplex ultrasound imaging.
  • CEAP classification of C2, C3 or C4.
  • Ability to walk unassisted.
  • Ability to attend follow-up visits.
  • Ability to understand the requirements of the study and to provide written informed consent.
  • "GSV" on standing pre-procedure Doppler Ultrasound ≥3mm and ≤10mm (maximum diameter).

Exclusion Criteria:

  • Life expectancy < 1 year.
  • Regular pain medication.
  • Anticoagulation including Heparin or Coumadin.
  • Previous Deep Vein Thrombosis "DVT".
  • Previous superficial thrombophlebitis in "GSV".
  • Previous venous treatment on target limb.
  • Known Hyper-coagulable disorder.
  • Conditions which prevent routine vein treatment like:

    • Acute disease,
    • Immobilization or inability to ambulate, and
    • Pregnancy.
  • Tortuous "GSV", which in the opinion of the Investigator will limit catheter placement. (no 2 primary access sites allowed).
  • Incompetent ipsilateral small saphenous or anterior accessory great saphenous vein.
  • Known sensitivity to the cyanoacrylate "CA" adhesive.
  • Current participation in another clinical study involving an investigational agent or treatment, or within the 30 days prior to enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01570101

Layout table for location information
Naestved, Denmark, 4700
Hamburg, Germany, 20354
Klinik Proebstle
Mannheim, Germany, D - 68161
Centrum Oosterawal
Alkmaar, Netherlands
United Kingdom
Countess of Chester Hospital NHS Foundation Trust
Chester, United Kingdom, CH2 1UL
The Whiteley Clinic
Guildford, United Kingdom, GU2 7RF
Charing Cross Hospital
London, United Kingdom, W6 8RF
Sponsors and Collaborators
Medtronic Endovascular
Layout table for investigator information
Principal Investigator: Thomas Proebstle, MD Klinik Proebstlé

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medtronic Endovascular Identifier: NCT01570101    
Other Study ID Numbers: CP-10763-01
First Posted: April 4, 2012    Key Record Dates
Last Update Posted: May 3, 2016
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Venous Insufficiency
Vascular Diseases
Cardiovascular Diseases